ARTICLE | Clinical News
Tresiba insulin degludec: Phase IIIb data
February 8, 2016 8:00 AM UTC
Top-line data from the double-blind, crossover, U.S. Phase IIIb SWITCH 2 trial in 721 Type II diabetics showed that once-daily subcutaneous Tresiba plus metformin met the primary endpoint of reducing ...